PIK3CA and cancer: PI3K, a phosphoinositide 3-kinase, is upregulated in several human cancers, with oncogenic mutations discovered in the p110-alpha catalytic and p85-alpha regulatory subunits that serve as a docking site during the drug development phase [70, 83].